百泰生物药业有限公司

About 百泰生物药业有限公司

Founded in August 2000, Baitaibio is the highest-level and largest investment cooperation project between China and Cuba in the field of biotechnology. The company's main focus is on the research and development and production of humanized monoclonal antibodies and vaccines for the treatment of malignant tumors, undertaking major national projects such as the National High-Tech Industrial Research and Development Plan and the National High-Tech Industrialization Demonstration Project. Baitaibio possesses China's first world-class antibody humanization technology platform, representing the core technology and mainstream direction of international biomedical development. The company has designed and built China's first fully automated large-scale mammalian cell culture production line, which is currently the largest, most complete, and most advanced large-scale cell culture technology platform in China. Baitaibio has successfully developed China's first humanized monoclonal antibody drug - Taisins, which received the Class I New Biologic Drug Certificate issued by the State Food and Drug Administration in April 2005, filling the gap in China's humanized monoclonal antibody drugs. Taisins specifically targets tumor cells for targeted therapy, killing tumor cells without damaging normal tissues, representing the latest development trend in the field of tumor treatment. Clinical studies have shown that Taisins alone or in combination with radiotherapy and chemotherapy has significant efficacy and low side effects in various cancers such as head and neck cancer, colorectal cancer, glioma, and non-small cell lung cancer, possessing high clinical application value. While actively carrying out international technology transformation, Baitaibio is committed to cultivating independent innovation capabilities. New drugs under development include the EGF vaccine for cancer treatment, humanized anti-CD6 monoclonal antibody for psoriasis and rheumatoid arthritis, and anti-CD3 monoclonal antibody for reversing organ transplant rejection. As a developing company, Baitaibio aims to become a modern large-scale biopharmaceutical enterprise, with the mission of improving antibody drug R&D capabilities and production levels and enhancing public health. Through an internationalized, industrialized, standardized, and scaled operating model, the company is dedicated to integrating the latest achievements in biotechnology development into the health industry of the 21st century, continuously contributing the most advanced and excellent antibody drugs to society, and witnessing the rise of China's life sciences and biomedicine together with you!